A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer letters"
DOI: 10.1016/j.canlet.2017.05.015
Abstract: KRAS mutation is the most common genetic event in pancreatic cancer. Whereas KRAS itself has proven difficult to inhibit, agents that target key downstream signals of KRAS, such as RAF, are possibly effective for pancreatic… read more here.
Keywords: using yap; pancreatic cancer; kras mutant; strategy using ... See more keywords